Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
267 studies found for:    E-101
Show Display Options
Rank Status Study
1 Recruiting Efficacy and Safety of E-101 Solution for Preventing Surgical Site Infections After Colorectal Surgery
Condition: Infections
Interventions: Drug: E-101 Solution 300 GU/ml;   Drug: Saline solution
2 Completed PuLsE 2-Observational Long-Term Effectiveness Follow-Up Study of PuLsE 1
Condition: Epilepsy
Intervention:
3 Completed Single Ascending Dose Study Using DS-1971 to Assess Safety, Tolerability, and Pharmacokinetics in Healthy Participants.
Conditions: Safety;   Tolerability;   Pharmacokinetics
Interventions: Drug: DS-1971;   Drug: placebo
4 Recruiting Study of the Therapeutic Vaccine (ISA101) to Treat Advanced or Recurrent Cervical Cancer
Condition: Cervical Cancer
Intervention: Drug: ISA101
5 Completed Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)
Condition: Alzheimer's Disease
Interventions: Drug: E2609;   Drug: Placebo for E2609
6 Active, not recruiting A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Biological: IMM-101;   Drug: Gemcitabine
7 Completed Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Intervention: Drug: PXD101
8 Recruiting CLLR3: FC + GA101 and B + GA101 in Relapsed or Refractory CLL Followed by GA101 Maintenance for Responding Patients
Condition: Chronic Lymphocytic Leucemia
Interventions: Drug: FC+ GA101;   Drug: B+ GA101
9 Recruiting APG101 in Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Interventions: Drug: Treatment with APG101;   Procedure: Bone marrow collection;   Procedure: Blood drawings
10 Completed Phase I Study to Compare NP101(Sumatriptan Iontophoretic Transdermal Patch) With Three Formulations of Imitrex®
Condition: Healthy
Intervention: Drug: Sumatriptan succinate
11 Terminated DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])
Condition: Prostate Cancer
Interventions: Drug: calcitriol;   Drug: docetaxel
12 Completed Interactive Training in Sports Concussion Prevention and Management
Condition: Concussion
Interventions: Other: Brain 101 website;   Other: Control
13 Completed Phase 3 Study of ATX-101 Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area
Condition: Healthy
Interventions: Drug: ATX-101;   Drug: Placebo
14 Recruiting A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.
Condition: Cardiovascular Diseases
Interventions: Drug: AMR101;   Drug: Placebo
15 Active, not recruiting Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101
Conditions: Submental Fat;   Healthy
Interventions: Drug: ATX-101;   Drug: Placebo
16 Completed Safety, Efficacy and Pharmacokinetics of OPC-67683 in Patients With Pulmonary Tuberculosis
Condition: Pulmonary Tuberculosis
Interventions: Drug: OPC-67683;   Drug: Rifafour e-275
17 Terminated A Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Interventions: Drug: Menatetrenone;   Drug: Placebo
18 Active, not recruiting Efficacy and Safety of Idelalisib (GS-1101; CAL-101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Idelalisib;   Drug: Ofatumumab
19 Recruiting An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
Conditions: Malignant Solid Tumour;   Ovarian Cancer;   Triple Negative Breast Cancer;   Advanced Melanoma;   B-cell Malignancy, Low-grade
Interventions: Drug: E7449 alone;   Drug: E7449 plus TMZ;   Drug: E7449 plus carboplatin and paclitaxel
20 Recruiting Prospective Controlled Cohort Study on the Safety of a Monophasic Oral Contraceptive Containing Nomegestrol Acetate (2.5mg) and 17ß-estradiol (1.5mg)
Condition: Contraception
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years